Catalent, Inc. Announces Second Quarter Fiscal Year 2022 Earnings Conference Webcast
21 Januar 2022 - 2:15PM
Business Wire
Catalent, the leading global provider of advanced delivery
technologies, development, manufacturing and clinical supply
solutions for drugs, biologics, cell and gene therapies, as well as
consumer health products, today announced that it will release
financial results for the second quarter of fiscal year 2022 ended
December 31, 2021, before the market open on Tuesday, February 1,
2022. The Company’s management will host a webcast to discuss the
results at 8:15 a.m. ET on the same day.
Catalent invites all interested parties to listen to the
webcast, which will be accessible through Catalent’s website at
http://investor.catalent.com.
A supplemental slide presentation will also be available in the
“Investors” section of Catalent’s website prior to the start of the
webcast. The webcast replay, along with the supplemental slides,
will be available for 90 days in the “Investors” section at
www.catalent.com.
About Catalent, Inc.
Catalent, Inc. (NYSE: CTLT), an S&P 500® company, is the
global leader in enabling pharma, biotech, and consumer health
partners to optimize product development, launch, and full
life-cycle supply for patients around the world. With broad and
deep scale and expertise in development sciences, delivery
technologies, and multi-modality manufacturing, Catalent is the
industry’s preferred partner for personalized medicines, consumer
health brand extensions, and blockbuster drugs. Catalent helps
accelerate over 1,000 partner programs and launch over 150 new
products every year. Its flexible manufacturing platforms at over
50 global sites supply over 70 billion doses of nearly 7,000
products to over 1,000 customers annually. Catalent’s expert
workforce exceeds 17,000, including more than 2,500 scientists and
technicians. Headquartered in Somerset, New Jersey, the company
generated $4 billion in revenue in its 2021 fiscal year. For more
information, visit www.catalent.com.
More products. Better treatments. Reliably supplied.™
View source
version on businesswire.com: https://www.businesswire.com/news/home/20220121005009/en/
Investor Contact: Paul Surdez, Catalent, Inc. (732) 537-6325
investors@catalent.com
Catalent (NYSE:CTLT)
Historical Stock Chart
Von Jun 2024 bis Jul 2024
Catalent (NYSE:CTLT)
Historical Stock Chart
Von Jul 2023 bis Jul 2024